This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Metz, J. T. Articles by Cooper, D. J. Search for Related Content Social Bookmarking                         What's this?

Neuroimaging in Drug Discovery and Development: Paradigms for Accelerating New Drug Availability

MIICRO, Inc., Suite 107, 1021 W. Adams, Chicago, IL 60607, jmetz{at}miicro.com

Malcolm D. Cooper

Department of Radiology, University of Chicago Hospitals, 5841 S. Maryland, Chicago, IL 60637, MIICRO, Inc., Suite 107, 1021 W. Adams, Chicago, IL 60607

Terry F. Brown

MIICRO, Inc., Suite 107, 1021 W. Adams, Chicago, IL 60607

Leann H. Kinnunen

Department of Psychology, University of Chicago, 5848 S. University Avenue, Chicago, IL 60637 and MIICRO, Inc., Suite 107, 1021 W. Adams, Chicago, IL 60607

Declan J. Cooper

MIICRO, Inc., Suite 107, 1021 W. Adams, Chicago, IL 60607

The process of discovering and developing new drugs is complicated. Neuroimaging methods can facilitate this process. An analysis of the conceptual bases and practical limitations of different neuroimaging modalities reveals that each technique can best address different kinds of questions. Radioligand studies are well suited to preclinical and Phase II questions when a compound is known or suspected to affect well-understood mechanisms; they are also useful in Phase IV to characterize effective agents. Cerebral blood flow studies can be extremely useful in evaluating the effects of a drug on psychological tasks (mostly in Phase IV). Glucose metabolism studies can answer the simplest questions about whether a compound affects the brain, where, and how much. Such studies are most useful in confirming central effects (preclinical and early clinical phases), in determining effective dose ranges (Phase II), and in comparing different drugs (Phase IV).

Key Words: positron emission tomography (PET) • functional magnetic resonance imaging (fMRI) • drug development • cerebral blood flow • cerebral glucose metabolism

Journal of Pharmacy Practice, Vol. 14, No. 5, 407-415 (2001)
DOI: 10.1106/BX9P-GCM4-GTEF-JGHN


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?